


## SUPPLEMENTAL DATA

### **Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM**


Andrew McKinney<sup>1</sup>, Olle R. Lindberg<sup>1</sup>, Jane R. Engler<sup>1</sup>, Katharine Y. Chen<sup>1</sup>, Anupam Kumar<sup>1</sup>, Henry Gong<sup>1</sup>, Kan V. Lu<sup>1</sup>, Erin F. Simonds<sup>1,2</sup>, Timothy F. Cloughesy<sup>3,4</sup>, Linda M. Liao<sup>3,5</sup>, Michael Prados<sup>1</sup>, Andrew W. Bollen<sup>6</sup>, Mitchel S. Berger<sup>1</sup>, Joseph T.C. Shieh<sup>7,8</sup>, C. David James<sup>9</sup>, Theodore P. Nicolaides<sup>1,10</sup>, William H. Yong<sup>11</sup>, Albert Lai<sup>3,4</sup>, Monika E. Hegi<sup>12</sup>, William A. Weiss<sup>1,2,10</sup>, Joanna J. Phillips<sup>1,6</sup>.

**Supplemental Figure S2. DEAB inhibits erlotinib-induced invasion and ALDH1A1 expression in parental CSCs. (A-B)** Addition of DEAB inhibits erlotinib-induced invasion in 3D invasion assays. **(C)** Very low level ALDH1A1 expression in parental CSCs relative to positive control Hep2G cells by Western. Note background band present in all mouse cells of approximately 65 kDa. Representative images and quantification, mean  $\pm$  SEM (n=6). \*\*\*p<0.001.

A



B



C

